Skip to main
ACRS
ACRS logo

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

Aclaris Therapeutics (ACRS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclaris Therapeutics Inc has a promising outlook due to its focus on novel drug candidates targeting immuno-inflammatory diseases, with a significant portion of its revenue stemming from the therapeutics segment. Early data for its drug candidate Bosakitug indicates that it may exhibit improved efficacy compared to established treatments like Dupixent, which enhances its competitive position in the market. Additionally, positive patient reported outcomes, including significant improvements in secondary endpoints such as the loss-of-smell score and sleep domain metrics, further bolster the potential for successful product development and future revenue growth.

Bears say

Aclaris Therapeutics Inc demonstrates a concerning outlook as major clinical endpoints show limited efficacy, with only 9% of patients in two cohorts experiencing a meaningful reduction in pruritus, while 50% of patients in another cohort achieved a similar reduction. Additionally, the efficacy data from the placebo group reveals a substantial 39.7% reduction in the EASI score, raising concerns about the comparative effectiveness of Aclaris's treatments. The company's reliance on its therapeutics segment for revenue is further jeopardized by these disappointing clinical trial results, potentially undermining investor confidence in its product pipeline.

Aclaris Therapeutics (ACRS) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclaris Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclaris Therapeutics (ACRS) Forecast

Analysts have given Aclaris Therapeutics (ACRS) a Buy based on their latest research and market trends.

According to 7 analysts, Aclaris Therapeutics (ACRS) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclaris Therapeutics (ACRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.